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Abstract
Background: The management of early breast cancer (BC) with skin-sparing mastectomy (SSM) and immediate breast 
reconstruction (IBR) is not based on level-1 evidence. In this study, the oncological outcome, post-operative morbidity 
and patients' satisfaction with SSM and IBR using the latissimus dorsi (LD) myocutaneous flap and/or breast prosthesis 
is evaluated.
Methods: 137 SSMs with IBR (10 bilateral) were undertaken in 127 consecutive women, using the LD flap plus implant 
(n = 85), LD flap alone (n = 1) or implant alone (n = 51), for early BC (n = 130) or prophylaxis (n = 7). Nipple 
reconstruction was performed in 69 patients, using the trefoil local flap technique (n = 61), nipple sharing (n = 6), skin 
graft (n = 1) and Monocryl mesh (n = 1). Thirty patients underwent contra-lateral procedures to enhance symmetry, 
including 19 augmentations and 11 mastopexy/reduction mammoplasties. A linear visual analogue scale was used to 
assess patient satisfaction with surgical outcome, ranging from 0 (not satisfied) to 10 (most satisfied).
Results: After a median follow-up of 36 months (range = 6-101 months) there were no local recurrences. Overall breast 
cancer specific survival was 99.2%, 8 patients developed distant disease and 1 died of metastatic BC. There were no 
cases of partial or total LD flap loss. Morbidities included infection, requiring implant removal in 2 patients and 1 
patient developed marginal ischaemia of the skin envelope. Chemotherapy was delayed in 1 patient due to infection. 
Significant capsule formation, requiring capsulotomy, was observed in 85% of patients who had either post-
mastectomy radiotherapy (PMR) or prior radiotherapy (RT) compared with 13% for those who had not received RT. The 
outcome questionnaire was completed by 82 (64.6%) of 127 patients with a median satisfaction score of 9 (range = 5-
10).
Conclusion: SSM with IBR is associated with low morbidity, high levels of patient satisfaction and is oncologically safe 
for T(is), T1 and T2 tumours without extensive skin involvement.
Background
The overarching principle guiding surgical management
of women with breast cancer (BC) remains oncological
safety. The mainstay of satisfactory local control contin-
ues to be adequate clearance of the primary tumour and
involved axillary lymph nodes. Improvements in our
understanding of tumour biology have enabled the risk of
loco-regional recurrence (LR) and distant events to be
further reduced by adjuvant, or neo-adjuvant, radiother-
apy and systemic treatments. In keeping with this, breast-
conserving therapy (BCT) has become well established as
the treatment of choice for most women with early BC.
However, approximately one-third of women still
undergo mastectomy, either due to patient preference or
in cases where breast conservation is not oncologically or
aesthetically compatible with the size or distribution of
disease. Despite the relative frequency of mastectomy,
guidance from level-1 evidence is lacking in regard to the
optimal type of mastectomy which should be performed
and the subsequent technique and timing of breast recon-
struction.
Skin sparing mastectomy (SSM) involves the en-bloc
removal of all glandular tissue including the nipple-areola
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complex (NAC) and in some cases adjacent biopsy scars
and skin overlying superficial tumours. In contrast to
conventional mastectomy, there is maximal preservation
of the remaining breast skin envelope and infra-mam-
mary fold [1]. SSM can therefore facilitate immediate
breast reconstruction (IBR) with autologous tissue and/or
prosthetic implants by utilising the native skin envelope
to optimise the contour, texture, colour and scarring of
the reconstructed breast [1]. This approach combines the
ablative and reconstructive components of surgical inter-
vention, offering a single-stage procedure which is likely
to be popular with patients in terms of hospital admis-
sions, return to employment and elimination of the post-
mastectomy pre-reconstruction period.
The aesthetic advantages of SSM have been tempered
to some degree by concerns regarding oncological safety.
In comparison with conventional mastectomy, the com-
plete excision of glandular tissue during SSM can be tech-
nically more demanding. In addition, there is a perceived
increase in the risk of LR attributed to preservation of the
skin envelope. Indeed, following conventional mastec-
tomy the most common site for LR is within the skin
overlying the chest wall and post-mastectomy radiother-
apy (PMR) is recommended for those at high-risk. More
than one-third of breast surgeons have been reported to
avoid SSM and IBR because of concerns over oncological
safety or unc ertainty of t he benefits or indica tions [2].
More recently, several studies have contributed to the
evidence base supporting the oncological adequacy of
SSM in selected early-stage BC, excluding inflammatory
BC and tumours with extensive involvement of the skin
[1].
In this study the oncological safety, post-operative mor-
bidity and patients' satisfaction with SSM and IBR using
the latissimus dorsi (LD) myocutaneous flap and/or
breast prosthesis is evaluated in a prospective cohort of
women with early-stage BC.
Methods
The prospective cohort consisted of 127 consecutive
women with early-stage BC treated within three indepen-
dent sector healthcare centres in London. All patients
provided informed consent for their inclusion in the pro-
spective observational study, including the use of images
within the manuscript. Selection criteria included women
with a pre-operative diagnosis (clinical examination,
imaging and needle biopsy) of Tis, T1 and T2 tumours
without extensive skin involvement. Only 1 patient
included in the study had T3 BC. The principal indication
for surgery was BC, however, 7 procedures were under-
taken as risk-reducing prophylactic mastectomies (1
BRCA-1 gene carrier, 5 contra-lateral BC). All patients
were counselled pre-operatively regarding the ablative
and reconstructive options available and surgical recom-
mendations were made on a case-by-case basis following
discussion of tumour and patient factors within the con-
text of a multidisciplinary team. Patient related factors
included body habitus, size and shape of breasts, co-mor-
bidities, history of smoking and patient preference.
Surgical procedures were performed by the same sur-
geon (K.M.) between 2001 and 2008. All 127 women
underwent SSM and IBR, with 117 unilateral and 10
bilateral procedures, providing a total of 137 cases. Nip-
ple-sparing mastectomy (NSM) and IBR were undertaken
in 10 cases (6 patients). IBR employed the LD pedicle-flap
and implant (n = 85, including 1 bilateral case), LD flap
alone (n = 1) or implant only (n = 51, including 9 bilateral
cases), Figures 1, 2, 3, 4, 5 and 6. Information regarding
reconstructive options was provided to all patients pre-
operatively. Multidisciplinary recommendations were
subsequently made on an individual basis, reflecting the
aforementioned tumour and patient factors. In particular,
LD pedicle-flap and implant reconstructions were under-
taken in those women for whom an implant only recon-
struction would not provide satisfactory cosmesis. In
some cases, the intention was not simply to match the
reconstructed breast as closely as possible to the contra-
lateral breast, but rather to provide the patient with a
more satisfactory 'matching pair' of breasts by enhance-
ment or reduction of the native breast. Hence, thirty
patients underwent contra-lateral surgery in order to
optimize symmetry and cosmesis. These procedures con-
sisted of 19 augmentations and 11 mastopexy/reduction
mammoplasties. The initial implant used in all cases was
a tissue expander, in order to optimise the size and shape
of the reconstructed breast. This was subsequently
replaced in most patients, with an anatomically profiled
bio-dimensional cohesive silicon implant, at the same
time as nipple reconstruction or contra-lateral adjust-
ment thus adding no unnecessary surgical episodes. Nip-
ple reconstruction was performed in 69 patients using the
trefoil local flap technique (n = 61), nipple sharing (n = 6),
skin graft (n = 1) and Monocryl mesh (n = 1), Figures 4
and 5.
Patients at high risk of requiring PMR were encouraged
to opt for SSM and IBR using an implant alone (tissue
expander). Following PMR, these patients were reviewed
to assess the need for delayed conversion to an autolo-
gous flap with exchange of the tissue expander for defini-
tive prosthesis, particularly if the aesthetic outcome was
significantly compromised. We adopted this 'immediate-
delayed' strategy in 11 cases. All patients underwent clin-
ical examination on a six monthly basis and annual sur-
veillance mammography. The patient's satisfaction with
the outcome of surgery was assessed using a linear visual
analogue scale, ranging from 0 (not satisfied) to 10 (most
satisfied), through a postal questionnaire, Additional FileReefy et al. BMC Cancer 2010, 10:171
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Figure 1 Skin sparing mastectomy and latissimus dorsi reconstruction. (a) Left skin sparing mastectomy and latissimus dorsi myocutaneous flap 
reconstruction in a 45 year old woman prior to nipple reconstruction and tattooing. (b) Magnified view of left side.
(a) 
(b) Reefy et al. BMC Cancer 2010, 10:171
http://www.biomedcentral.com/1471-2407/10/171
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Figure 2 Skin sparing mastectomy and implant reconstruction. (a) Right skin sparing mastectomy and implant reconstruction. (b) Left skin spar-
ing mastectomy and implant reconstruction in a 70 year old woman.
(a) 
(b)  Reefy et al. BMC Cancer 2010, 10:171
http://www.biomedcentral.com/1471-2407/10/171
Page 5 of 12
Figure 3 Nipple sparing mastectomy and implant reconstruction. (a) Bilateral nipple-sparing mastectomy and implant reconstruction. (b) Bilat-
eral nipple-sparing mastectomy and implant reconstruction for bilateral breast cancer in a 57 year old woman.
(a)  
(b)  Reefy et al. BMC Cancer 2010, 10:171
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1. The mean time from treatment to issue of the ques-
tionnaire was approximately 18 months.
Surgical Considerations
In the majority of cases SSM was performed through a
peri-areolar incision. In a small number of women the
peri-areolar incision provided inadequate access to
remove all glandular tissue and additional short horizon-
tal incisions at the 3 and 9 o'clock positions were guided
by breast size, profile and skin laxity. The infra-mammary
fold was preserved in all cases. In patients who under-
went NSM, the tumour was always more than 2.5 cm
from the NAC and an intra-operative frozen-section pro-
tocol was followed to ensure that the retro-areola tissue
was tumour free. All mastectomy specimens were sent for
definitive histopathological analysis. All patients had pre-
operative axillary ultrasound +/- fine needle aspiration
cytology (FNAC) and those with negative axillae under-
went sentinel lymph node biopsy (SLNB) using blue dye
and/or radioactive isotope tracer, usually through a sepa-
rate short axillary incision. The SLNB protocol evolved
during the course of the study; between 2001-2004 the
technique was based on a blue-dye guided sample aiming
to retrieve four nodes, whereas between 2005-2009 the
dual localization technique was utilised. Immediate axil-
lary node clearance was performed if intra-operative fro-
zen section analysis of the SLNB showed malignancy.
Subsequent replacement of the tissue expander with
definitive implant prosthesis was performed through
short infra-mammary incisions. The prosthesis was
placed in a sub-muscular pocket in all cases. Negative
suction drains were used in all patients at the LD donor
site and adjacent to the prosthetic implants. All patients
received prophylactic antibiotics and low molecular
weight heparin.
Results
The median patients' age was 47 years (range = 27-72).
Histopathological analysis of mastectomy specimens
showed pure DCIS in 25 cases and invasive carcinoma (+/
- DCIS) in 105 cases, Table 1. One patient carrying
BRCA-1 gene mutation had bilateral prophylactic mas-
Figure 4 Nipple reconstruction. Nipple reconstruction followed by tattooing.Reefy et al. BMC Cancer 2010, 10:171
http://www.biomedcentral.com/1471-2407/10/171
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tectomies with normal histology. The median tumour
size was 28 mm (range 1 mm - 100 mm) and in all cases
the superficial surgical margins were clear with no cancer
cells at the surgical margins on microscopic examination.
In two patients with extensive multi-centric disease the
tumour extended to the medial surgical margin (focal
DCIS only) and one of these patients received PMR.
Lymph nodes were found to be involved in 45 patients, 41
of whom had macro-metastasis and a further 4 patients
had evidence of micro-metastatic spread within the senti-
nel node. In total, 23 patients had axillary clearance at the
first operation. Of these, 20 women were suspected to be
node positive pre-operatively by axillary ultrasound and
FNAC and this was confirmed on final histopathological
analysis. The other 3 patients were found to be node neg-
ative on definitive analysis, resulting from the fact that
SLNB was not available during the first month of the
study. The remainder of the cohort had intra-operative
SLNB to stage the axilla, proceeding to immediate axil-
lary clearance if indicated by positive frozen section anal-
ysis. We observed no cases which were intra-operatively
negative by frozen section and subsequently positive on
final histopathological analysis, hence no patients
returned to theatre for completion clearance. Adjuvant
chemotherapy was required by 38 patients. Prior RT had
been received by 6 patients, who had previously under-
gone BCT for cancer, comprising wide-local excision and
adjuvant RT. They subsequently developed recurrence
and were managed with SSM & IBR. In addition, 21
women underwent PMR (LD flap and implant recon-
struction = 10, implant only reconstruction = 11).
There was no LR after a median follow-up of 36 months
(range = 6-101 months). Overall survival was 99.2%. Eight
patients developed distant disease and one patient died of
metastatic breast cancer. One other patient died of lung
cancer. In our series, we observed no cases of partial or
total LD flap loss. Morbidities included infection, requir-
ing implant removal in 2 patients and 1 patient (smoker)
developed marginal ischaemia of the skin envelope which
was treated conservatively. Six patients had previous RT
Figure 5 Skin sparing mastectomy and latissimus dorsi flap with nipple reconstruction. Left skin sparing mastectomy and latissimus dorsi myo-
cutaneous flap reconstruction, followed by nipple reconstruction and tattooing.Reefy et al. BMC Cancer 2010, 10:171
http://www.biomedcentral.com/1471-2407/10/171
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and none of them developed wound complications. Neg-
ative suction drains were used in all patients with a
median period of 5 days for the LD donor-site and 3 days
for drains adjacent to prosthetic implants. All patients
undergoing LD flap reconstruction developed donor-site
seromas which required percutaneous drainage in the
outpatient setting; the median inpatient stay was 5 days.
Chemotherapy was delayed by 2 weeks in 1 patient due to
infection. In 2 patients excessive oozing from the LD har-
vest site resulted in a decrease in haemoglobin sufficient
Figure 6 Skin sparing mastectomy and extended latissimus dorsi flap with nipple reconstruction. Right SSM and IBR using an extended LD 
flap without an implant in a 56 year old woman. She subsequently had nipple reconstruction using a free graft from the left nipple.
Table 1: The histological findings in SSM specimens (n = 137) classified according to the TNM stage at diagnosis.
TNM stage No. of cases Local Recurrence Distant Recurrence
Tis 23 0 0
T i s N 1 200
T1N0 M0 47 0 2
T1N1 M0 16 0 0
T2N0 M0 15 0 2 (one mortality)
T2N1 M0 26 0 4
T 3 N 1  M 0 100
N o r m a l / B e n i g n700
Total 137 08Reefy et al. BMC Cancer 2010, 10:171
http://www.biomedcentral.com/1471-2407/10/171
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to necessitate blood transfusion (<8 g/dL), however this
was self limiting in both cases and no re-operation was
needed. There were no admissions to the intensive care
unit. Significant capsule formation was observed in
approximately 85% (23/27) of patients who had either
prior RT or PMR, which was substantially greater than
the 13% (13/100) for those patients who had not received
any RT. Capsule formation was corrected with capsulo-
tomy at the time of exchanging the tissue expander for
definitive prosthesis. However, one patient required a
second capsulotomy several months after placement of
the definitive prosthesis. Eighty-two (64.6%) of 127
patients completed the satisfaction survey with a median
score of 9 (range = 5-10). There was no significant differ-
ence in satisfaction scores between patients undergoing
IBR using LD flap and implant reconstruction (mean =
9.3, median = 10) and those undergoing implant only
reconstruction (mean = 9, median = 10).
Discussion
Over the last two decades there has been a paradigm shift
in the surgical management of BC away from radical and
ablative surgery towards a more tailored and conservative
approach. Improvements in our understanding of the
natural history and tumour biology of BC, alongside the
advent of evidence-based adjuvant local and systemic
therapies, have concluded the era where oncological
safety and aesthetic outcome were perceived to be mutu-
ally exclusive. BCT now represents the standard of care
for women with early-stage BC. In keeping with this evo-
lution in surgical practice, SSM can be considered part of
the rational progression away from conventional mastec-
tomy. Several studies have recently evaluated SSM for BC
and found the incidence of LR to comparable to conven-
tional mastectomy. In a 15 year retrospective series of
women with stage 0-2 IBC, 225 patients undergoing SSM
and IBR were compared to 1022 patients treated by con-
ventional mastectomy. After an average follow-up of 49
months, there was found to be no significance difference
in LR [3]. After an average follow-up of 51 months, Mere-
toja et al. reported only 4 LRs within the native breast
skin of 146 women with stage 0-2 IBC. Following surgical
and oncological treatment none of these patients devel-
oped new recurrences after a mean of 35 months, sug-
gesting that not all LRs are associated with disseminated
disease [4]. In another series of 105 patients undergoing
SSM and IBR, followed-up for an average of 48 months,
only one case of LR was identified [5]. In their retrospec-
tive study with an average follow-up of 58 months,
Vaughan et al. found 11(5.3%) cases of LR in 210 SSMs
with IBR, 9 of which developed in the quadrant of the
corresponding primary tumour [6]. In our series, we
observed no cases of LR after a median follow up of
a p p r o x i m a t e l y  3  y e a r s .  A l t h o u g h  l o n g e r  f o l l o w  u p  i s
required, the present study adds to the growing body of
evidence that SSM is oncologically safe for early stage
breast cancer (Tis, T1 and T2 tumours) without extensive
skin involvement [1,7]. Evidence in support of the onco-
logical adequacy of SSM in selected cases continues to
increase in quantity, quality and maturity of the data. A
recent postal questionnaire survey of 370 Californian sur-
geons suggests that attitudes and practices may also be
changing, with 90% of respondents satisfied with onco-
logical adequacy and 70% in agreement with regard to
superior aesthetic outcome [8]. Our series also included
one patient with a T3 tumour, although the utility of SSM
and IBR in this subgroup has been controversial, particu-
larly with regard to the risk of LR within the preserved
skin envelope [9]. One study of 25 patients with locally
advanced breast cancer (stage IIB/stage III), found an LR
rate of 4% after a median follow-up of 49 months [10].
However, a retrospective study of 207 women undergoing
SSM and IBR, with a mean follow-up of 70 months, 5.8%
of patients with stage 0-2 disease developed LR, com-
pared to 31% of women with stage 3 BC [11]. Recognised
risk factors for LR after SSM and IBR include: tumour
size, stage, poor differentiation and lymph node involve-
ment [12]. Uriburu et al. [13] also recommend surgical
resection of any needle biopsy tracts at the time of SSM
to reduce the risk of biopsy site LR.
SSM can facilitate IBR by the advantages in contour,
colour, texture and scarring associated with preservation
of the native skin envelope. This approach can also
reduce the need for contra-lateral adjustment in order to
achieve symmetry [2,14]. In their study of 112 patients
who underwent SSM and IBR, Gerber et al [15] recently
reported a 91% patient satisfaction rate with aesthetic
outcome. The combination of ablative and reconstructive
procedures, offers a single-stage intervention which is
popular with patients in terms of hospital stay, return to
work and elimination of the post-mastectomy pre-recon-
struction period. In the present study, approximately
two-thirds of all patients completed the questionnaire
and the median patient satisfaction score was 9/10. This
study also demonstrates that IBR using an LD flap and/or
implant is an acceptable option for most patients without
the need for a more complex reconstruction using free
tissue transfer and micro-vascular surgery. The fact that
patients' satisfaction with the surgical and aesthetic out-
come was only assessed subjectively using an analogue
score represents an important limitation to our study. A
larger sample size would be required to detect small dif-
ferences between particular patient subgroups. Further-
more, patients' satisfaction may change over time,
particularly in women with implant-based reconstruc-
tions, and we shall continue to monitor this in the long-Reefy et al. BMC Cancer 2010, 10:171
http://www.biomedcentral.com/1471-2407/10/171
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term. Follow up is also required to assess the number of
procedures which may be necessary to deal to implant
complications.
SSM and IBR in our series carried a low morbidity. Skin
flap necrosis is well recognised and may result from com-
promised blood supply secondary to excessive undermin-
ing and thinning of the flaps. We observed only one case
of marginal ischemia of the skin envelope (1%) in a cur-
rent smoker. This complication has been estimated to
occur in 11% of SSM and non-SSM cases [16]. The low
incidence in our study may be attributed to the extreme
care taken during dissection in order to accurately iden-
tify and follow the superficial fascial plane between the
subcutaneous fat and the mammary tissue. Furthermore
the low rate of infection leading to implant loss (2%) in
our cohort can be attributed to the routine use of prophy-
lactic antibiotics. In the present study, a large proportion
of patients who underwent prior RT or PMR developed
capsular fibrosis and shrinkage, resulting in discomfort
and deformity. However, this complication was effectively
managed by capsulotomy at the time of exchanging the
tissue expander for definitive prosthesis. Surgical compli-
cations can compromise the aesthetic outcome of SSM
and IBR and this has been associated with a reduction in
patient satisfaction [17].
Skin-Sparing Mastectomy and Ductal Carcinoma In-Situ
Mastectomy can also be indicated in several non-invasive
conditions. DCIS may necessitate mastectomy when the
lesions are extensive, multi-centric or recurrent, however,
sometimes patients request to be managed in this way.
M a s t e c t o m y  f o r  DC I S  i s  a s s o c i a t e d  w i t h  c u r e  r a t e s  i n
excess of 98% [18]. In our study SSM and IBR was under-
taken for pure DCIS in 25 cases and there were no cases
of LR. In a study by Rubio et al. [19] where 95 patients
underwent SSM and IBR for DCIS, 98% were alive and
disease free after a median follow-up of 3.7 years. In 35
cases, intra-operative specimen radiography and histo-
logical examination of serial sections were used to con-
firm clearance of the margins and none of these
developed LR. The overall LR rate was 3%. The series by
Carlson et al. [20] included 175 patients with DCIS and
identified only 1 LR after 65 months of follow-up. Simi-
larly, Slavin et al. [21] reported no LR in a cohort of 26
patients with DCIS after 45 months of follow-up. Studies
with longer follow-up also provide evidence for oncologi-
cal safety, Spiegel and Butler [22] found no LR after 9.8
years. SSM and IBR is particularly attractive for women
with DCIS in view of the fact that PMR is not given to the
reconstructed breast and the risk of LR is very low.
Radiotherapy & Skin-Sparing Mastectomy
Most women who undergo SSM and IBR for early-stage
BC will not require PMR. However, PMR has been shown
to reduce LR and improve survival for patients with four
or more involved regional lymph nodes or tumours >5 cm
[23]. Complication rates of 5-16% have been reported
with PMR following autologous breast reconstruction
[2,16]. In a study of 377 implant reconstructions, morbid-
ities including pain and capsular contracture were
reported following PMR [24]. Indeed, patient satisfaction
has been found to be lower in those who undergo RT
(67% vs. 88%) [25]. Significant capsule formation was
observed in the majority of our patients who had PMR,
however, this was effectively treated with capsulotomy at
the time of implant replacement and we did not observe a
significant reduction in satisfaction scores. The manage-
ment of women who are likely to need PMR continues to
be controversial and some surgeons advocate a conven-
tional mastectomy and delayed reconstruction. More
recently, it has been suggested that the benefits of SSM
can be preserved in this subgroup using an 'immediate-
delayed' reconstructive technique [2]. A temporary sub-
pectoral tissue expander can be placed at the time of
SSM. Following PMR, delayed reconstruction can be per-
formed by replacing the expander with a myocutaneous
flap and/or implant. This approach avoids the potential
radiotherapy delivery problems and cosmetic disadvan-
tages associated with IBR followed by PMR [26]. We
employed this strategy in 11 patients who required PMR
in our series. Alternatively, prior to mastectomy, radio-
logical tumour size, analysis of core-biopsies and SNLB
could be used to assess the likelihood of PMR, thereby
facilitating patient selection. Randomised controlled tri-
als are now required to compare the oncological and aes-
thetic outcomes for those women who require PMR and
are treated by SSM and IBR, conventional mastectomy
with delayed reconstruction or immediate-delayed
reconstruction.
Nipple-Sparing Mastectomy & Immediate Breast 
Reconstruction
Several variations of the standard SSM have recently been
reported, including the NSM. Preservation of the NAC
offers aesthetic advantages and eliminates the need for
n i p p l e  r e c o n s t r u c t i o n  a s s o c i a t e d  w i t h  s t a n d a r d  S S M .
Oncological concerns regarding the risk of occult NAC
involvement have been assuaged to some extent by sev-
eral recent studies [2,27-29]. Voltura et al [30] recently
reported outcomes for 34 NSMs undertaken for cancer
(24 BC and 10 DCIS). In each case histological analysis of
the sub-areolar tissue was performed and only 2 cases
(5.9%) required subsequent NAC removal. These results
are in keeping with a similar study reported by
Wijayanayagam et al [31]. The risk of NAC involvement
has been corroborated in a larger retrospective series of
286 SSMs, 16 (5.6%) were found to contain tumour in the
NAC [27]. If multi-centric and sub-areolar tumours wereReefy et al. BMC Cancer 2010, 10:171
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excluded, the NAC was only involved in 3% of cases. Ger-
ber et al. [32] performed 112 SSMs in women whose
breast cancer was more than 2 cm from the NAC and
used frozen sections of the retro-areola tissue to deter-
mine NAC preservation. The cosmetic results were inde-
pendently evaluated as excellent or good in 91% and were
significantly better after NAC preservation. Only one LR
occurred in the NAC preservation group. Frozen section
analysis of the retro-areola tissue has been found to be
90.9% sensitive and 98.5% specific [33]. Using this
approach, Benediktsson and Perbeck have recently
reported LR rates of 28.4%, falling to 8.5% in those receiv-
ing PMR, in series of 216 women undergoing NSM after a
median follow-up of 13 years. These are comparable to
conventional mastectomy. Overall, 91% of all preserved
NACs were present at the end of the study. Furthermore,
LR was not found to be associated with a reduced overall
survival. Another series of 140 mastectomies found
tumour size and nodal positivity to be risk factors for
NAC involvement [28]. Furthermore, the primary
tumour was situated within 2.5 cm of the areola in all
cases in which the NAC was positive. A retrospective
study involving 217 mastectomy specimens by Simmons
et al. [29] reported NAC tumour involvement in 23 cases
(10.6%). It was also found that only 6.7% of small tumours
with up to two positive lymph nodes had NAC involve-
ment. Therefore, it would appear oncologically safe to
perform SSM with NAC preservation, provided the
tumour is not close to the nipple and a frozen section
protocol is followed.
Another variation of the standard SSM involves
removal of the nipple with areola preservation, termed
the areola-sparing mastectomy (ASM). The concept is
supported by Simmons et al. [29] who found that areola
involvement was only identified in 2 of the 23 positive
NACs. ASM can therefore maintain cosmesis and would
only require a subsequent nipple reconstruction, if
requested by the patient. Simmons et al. [34] have
reported a series of 17 cases with only a single complica-
tion (wound infection) over a 20-month period.
Conclusion
SSM and IBR is oncologically adequate in selected
patients with Tis, T1 and T2 tumours in the absence of
extensive skin involvement. The approach is associated
with high levels of patient satisfaction and low morbidity.
Randomised controlled trials are required to compare the
oncological and aesthetic outcomes for those women
who require PMR and are treated by SSM and IBR, con-
ventional mastectomy with delayed reconstruction or
immediate-delayed reconstruction.
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